Tagged with Oncology

USA Karyopharm Therapeutics’ Dr Michael G. Kauffman outlines the genesis of the company he co-founded with his wife, the approval journey of key product XPOVIO®, his ambitious internationalisation plans, and the challenges of being a biotech entrepreneur.   From my experience, many great ideas actually come from people unconstrained by the…

China The partnership between global pharma giant Eli Lilly and Chinese biotech Innovent Biologics, first initiated in March 2015, continues to bear dividends for both parties. The recent announcement that Lillly has struck a deal for the exclusive license of Innovent’s TYVYT® drug outside of China stands to catapult the Chinese…

Norway Ketil Widerberg of the Oslo Cancer Cluster highlights how Norway’s excellence in electronic health records can help the country stake out a position as a significant cancer research destination. Widerberg also highlights the Cluster’s work to bridge seemingly disparate actors right across the oncology value chain, its collaboration with the…

China Founded in 2009 by CEO Dr XU Ting, Alphamab started its journey as a protein engineering company with the ultimate dream of becoming, as many Chinese biotechs aspire, a global biotech company producing world-class innovations. To learn more about some of China’s most innovative and inspirational biotech stories, download our…

Belgium Pierre Fabre Benelux General Manager Kristel de Bisschop discusses the challenges and opportunities inherent in taking charge of an important affiliate against the backdrop of a group-wide transformation push and a global pandemic. de Bisschop also touches on key product launches in both oncology and dermatology, the synergies between these…

China Dr Zaiqi Wang, chairman and CEO of Chinese oncology biotech InxMed, highlights the vital importance of combination therapies in cancer treatment, assesses the level of innovation in China, and outlines his strategy for the company moving forward.   We believe, to make a meaningful impact on treatment, it is necessary…

Novartis Ameet Mallik, Executive VP and Head of Oncology for the US at Novartis Oncology highlights the company’s culture of ‘curious, inspired, and unbossed,’ how Novartis differentiates itself in a highly competitive oncology landscape, learnings from recent product launches, and how Novartis is working to make its CAR-T therapy more accessible…

USA In recent years the US has seen an overall decease in cancer deaths thanks to innovative medicines and treatments. However, much work remains to be done in targeting and eliminating cancers. Below we highlight data for cancer deaths and cases in the US per male and female populations.     …

Italy Menarini Group, the largest Italian pharmaceutical company by turnover, has made its first move into the US oncology market through the acquisition of Stemline Therapeutics.   The deal, said to be worth USD 677 million, was announced on 4 May 2020 and completed on 10 June. The acquisition of Stemline,…

Opinion Mike Glover, Vice President Global Head of Access and Pricing Strategy Oncology at GSK outlines that while new mathematical approaches to health technology assessment (HTA) have been hugely beneficial, a broader approach that includes the insights of individual people is necessary to truly drive forward better health outcomes.   The…

Morocco Morocco has made admirable progress in building a national oncology network in recent years, but the country’s cancer patients still face significant challenges in terms of accessing the latest therapies. Here, the Morocco heads of companies with global portfolios of innovative cancer treatments discuss the current situation and how they…

China PharmaBoardroom caught up with Alphamab Oncology’s founder, chairman and CEO Dr Xu Ting again 16 months after our last interview to hear about their successful HKEX IPO in December 2019, his commercial expectations for their flagship PD-1/PD-L1 product, and the impact of COVID-19 on their operations.   The core business…